

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Guangdong True Health Medical
Technology Development Co., Ltd.**
廣東真健康醫療科技開發股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2697)

Voluntary Announcement Regarding the Entering into of a Strategic Cooperation Framework Agreement with General Technology Liaoning Pharmaceutical Co., Ltd.

This announcement is made voluntarily by Guangdong True Health Medical Technology Development Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide the shareholders and potential investors of the Company with the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, on 22 August, 2026, the Company entered into a strategic cooperation framework agreement with General Technology Liaoning Pharmaceutical Co., Ltd. (“General Technology Liaoning Pharmaceutical”) in Shenyang. Both parties, focusing on the three northeastern provinces of China, will collaborate on the development of a minimally invasive oncology diagnosis and treatment system, compliant operation of equipment, and the enhancement of specialty capabilities. The cooperation will adopt various models, including the joint development of specialty services, equipment technical services and operating leases, to promote the standardized implementation of minimally invasive interventional oncology technologies. The project will strictly comply with relevant laws and regulations, and the required filings with the National Health Commission and medical insurance authorities will be completed prior to implementation.

General Technology Liaoning Pharmaceutical Co., Ltd. is the sole provincial-level platform company established in Liaoning Province by China Meheco Group Co., Ltd., a subsidiary of China General Technology (Group) Holding Co., Ltd., an important backbone state-owned enterprise directly administered by the central government of

PRC. This cooperation will accelerate the large-scale deployment of the Company's self-developed minimally invasive oncology surgical robots and specialty solutions in Northeast China, establish a replicable model for oncology specialties, and promote the upgrading of regional healthcare.

The Board believes that this cooperation will enable the parties to complement each other's strengths and enhance the Company's market influence, and that it is in the interests of the Company and all its shareholders.

By order of the Board
**Guangdong True Health Medical
Technology Development Co., Ltd.**
Cheong Hou Iam
Chairperson and Executive Director

Hong Kong, 25 August, 2026

As at the date of this announcement, the executive Directors are Ms. Cheong Hou Iam (Chairperson), Ms. Chen Miaoping and Ms. Guo Jian; the non-executive Director is Ms. Mo Jinling; and the independent non-executive Directors are Dr. Liu Lianggang, Mr. Ng Kun Seng Chris and Mr. Ma Jianming.